Andrew Kuykendall, MD, discusses the background, methods, and design of a phase 2 study which evaluated fedratinib.

Cipla has received final US FDA approval for its Nilotinib Capsules (50 mg, 150 mg, 200 mg) for the treatment of Philadelphia ...

Mumbai: Pharma major, Cipla, has received final approval from the United States Food and Drug Administration (USFDA) for the New Drug Application (‘NDA’) submitted for ‘Nilotinib Capsules 50, ...

Nilotinib is an FDA approved drug used for the treatment of Philadelphia Chromosome Positive CML, which is a cancer of blood ...

Cipla announced that it has received final approval from the United States Food and Drug Administration (USFDA) for the new drug application (NDA) submitted for 'Nilotinib Capsules 50, 150 and 200 mg' ...

In a press release issued after market hours on February 20, Cipla announced that it has received approval for Nilotinib ...

Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.

Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertiseFOSTER CITY, Calif., Feb. 20, ...

Triplet Regimen Yields Promising Response in Advanced-Phase Chronic Myeloid Leukemia Sep. 17, 2024 — According to new research, 80% of patients with previously untreated or relapsed/refractory ...

From bipolar disorder to hepatitis, and from strokes to development of magnetic resonance imaging, research tied to NIH ...

Preparations for pivotal-stage readiness of vididencel in AML on trackThe hard work of the Mendus team to advance the company's lead product vididencel in acute myeloid leukemia (AML) continued to pay ...